Fingerprint
Dive into the research topics of 'Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
Research output: Contribution to journal › Review article › peer-review
56
Scopus
citations